Knowledge is power in driving pharma commercialization success
Two Labs is an industry leader in all facets of pharma services. Our professional, experienced team offers a wealth of skills and knowledge to manage the complexities of pharma product commercialization, market access and market intelligence.
Two Labs is officially unveiling its State Drug Price Transparency (DPT) managed service offerings to help emerging pharmaceutical manufacturers navigate the evolving regulatory landscape imposed by each state's own independent reporting requirements. Read the press release.
REMS are FDA-mandated, post-marketing safety programs that can be required to appropriately balance a drug's benefits and risks to support safe use. These safety programs are most often required during the NDA or biologics license application (BLA) process to address risks identified in development.
"We've deepened our bench of experts by adding some of the most experienced REMS professionals to our team, including Melissa Landers," said Howard Miller, CEO of Two Labs.
Emerging manufacturers have a strength in how close to and how passionate they are about the science they are developing. But because they are hyper-focused on the groundbreaking science they're working on, it can be hard to come up from the weeds to put together the launch support that their product needs. And often, one of the most underestimated parts of that launch plan is medical communications.
As the cell and gene therapy market has exponentially grown in recent years — with some reports predicting it will reach $24.4 billion with 54 to 74 approvals by 2030 — many manufacturers are learning the hard way just how complex it can be to launch these products.
It’s no surprise that putting together a successful launch strategy for an oncology product is a complex process. And we’ve heard from many of our emerging pharma clients that it’s intimidating to see how saturated and competitive the landscape is.
